Article Information
PubMed
Published By
Online ISSN
History
- Received January 30, 2019
- Revision received May 13, 2019
- Accepted May 14, 2019
- Published online May 27, 2019.
Copyright & Usage
© 2019 Bullock et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Author Information
- Bonnie L Bullock1,
- Abigail K Kimball2,
- Joanna M Poczobutt1,
- Alexander J Neuwelt1,
- Howard Y Li1,3,
- Amber M Johnson1,
- Jeff W Kwak1,
- Emily K Kleczko1,
- Rachael E Kaspar2,
- Emily K Wagner1,
- Katharina Hopp1,
- Erin L Schenk1,
- Mary CM Weiser-Evans1,
- Eric T Clambey2 and
- Raphael A Nemenoff1⇑
- 1Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 2Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 3Veterans Affairs Medical Center, Denver, CO, USA
- Correspondence: raphael.nemenoff{at}ucdenver.edu
Funding
National Institutes of Health
R01 CA162226; CA236222RA NemenoffColorado Lung SPORE
P50 CA058187HY Li, RA NemenoffUnited States Department of Veterans Affairs Biomedical Laboratory Research and Development Service
IK2BX001282HY LiNIH/NCATS
TL1 TR001081BL BullockNIH
P30CA046934National Cancer Institute
P30CA046934NIH/NCATS
UL1 TR001082
In this Issue
Advertisement
Subjects
Related Articles
Cited By...
- Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer
- Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
- Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
- The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness